Penta-O-galloyl-β-D-glucose ameliorates inflammation by inhibiting MyD88/NF-κB and MyD88/MAPK signalling pathways

British Journal of Pharmacology

Volumn 170, Issue 5, 2013, Pages 1078-1091

  Jang, Se Eun ^a   Hyam, Supriya R ^a   Jeong, Jin Ju ^a   Han, Myung Joo ^a   Kim, Dong Hyun ^a  

^a Kyung Hee University   (South Korea)

Author keywords

inflammation; macrophage; MyD88; NF B; penta O galloyl D glucose

Indexed keywords

ANTIINFLAMMATORY AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 4; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MESALAZINE; MITOGEN ACTIVATED PROTEIN KINASE; MYELOID DIFFERENTIATION FACTOR 88; MYELOPEROXIDASE; PENTA O GALLOYL BETA DEXTRO GLUCOSE; PEPTIDOGLYCAN; PLANT MEDICINAL PRODUCT; SMALL INTERFERING RNA; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR RELA; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; C57BL 6 MOUSE; COLITIS; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG DOSE COMPARISON; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IMMUNOBLOTTING; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

INFLAMMATION; MACROPHAGE; MYD88; NF-ΚB; PENTA-O-GALLOYL-Β-D-GLUCOSE;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS; CELLS, CULTURED; COLITIS; COLON; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GASTROINTESTINAL AGENTS; HYDROLYZABLE TANNINS; INFLAMMATION MEDIATORS; INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES; MACROPHAGES, PERITONEAL; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED C57BL; MITOGEN-ACTIVATED PROTEIN KINASES; MOLECULAR SEQUENCE DATA; MYELOID DIFFERENTIATION FACTOR 88; NF-KAPPA B; PHOSPHORYLATION; RNA INTERFERENCE; TOLL-LIKE RECEPTOR 4; TRANSFECTION; TRINITROBENZENESULFONIC ACID;

EID: 84885658793     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12333     Document Type: Article

References (53)

1. Alexander SP, Mathie A, Peters JA, (2011). Guide to Receptors and Channels (GRAC), 5th edition. Br J Pharmacol 164 (Suppl. 1): S1-324.
2. Atreya R, Multer J, Fintoo S, Müllberg J, Jostock T, Wirtz S, et al. (2000). Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. Nat Med 6: 583-588.
3. Baldwin AS Jr, (1996). The NF-κB and IκB proteins: new discoveries and insights. Annu Rev Immunol 14: 649-681.
4. Binder V, (2004). Epidemiology of IBD during the twentieth century: an integrated view. Best Pract Res Clin Gastroenterol 18: 463-479.
5. Brightbill HD, Plevy SE, Modlin RL, Smale ST, (2000). A prominent role for Sp1 during lipopolysaccharide-mediated induction of the IL-10 promoter in macrophages. J Immunol 164: 1940-1951.
6. Cao S, Liu J, Song L, Ma X, (2005). The protooncogene c-Maf is an essential transcription factor for IL-10 gene expression in macrophages. J Immunol 174: 3484-3492.
7. Cario E, Podolsky DK, (2000). Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun 68: 7010-7017.
8. Chow JC, Young DW, Golenbock DT, Christ WJ, Gusovsky F, (1999). Toll-like receptor-4 mediates lipolysaccharide-induced signal transduction. J Biol Chem 274: 10689-10692.
9. Clemente TR, Dos Santos AN, Sturaro JN, Gotardo EM, de Oliveira CC, Acedo SC, et al. (2012). Infliximab modifies mesenteric adipose tissue alterations and intestinal inflammation in rats with TNBS-induced colitis. Scand J Gastroenterol 47: 943-950.
10. Das KM, Eastwood MA, McManus JP, Sircus W, (1973). The metabolism of salicylazosulphapyridine in ulcerative colitis. I. The relationship between metabolites and the response to treatment in inpatients. Gut 14: 631-641.
11. Djakpo O, Yao W, (2010). Rhus chinensis and Galla Chinensis-folklore to modern evidence: review. Phytother Res 24: 1739-1747.
12. Duchmann R, Kaiser I, Hermann E, Mayet W, Ewe K, Meyer zum Büschenfelde KH, (1995). Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease. Clin Exp Immunol 102: 448-455.
13. Dutra RC, Claudino RF, Bento AF, Marcon R, Schmidt EC, Bouzon ZL, et al. (2011). Preventive and therapeutic euphol treatment attenuates experimental colitis in mice. PLoS ONE 6: e27122.
14. Feldman KS, Sahasrabudhe K, Lawlor MD, Wilson SL, Lang CH, Scheuchenzuber WJ, (2001). In vitro and in vivo inhibition of LPS-stimulated tumor necrosis factor-alpha secretion by the gallotannin beta-D-pentagalloylglucose. Bioorg Med Chem Lett 11: 1813-1815.
15. Genfa L, Jiang Z, Hong Z, Yimin Z, Liangxi W, Guo W, et al. (2005). The screening and isolation of an effective anti-endotoxin monomer from Radix Paeoniae Rubra using affinity biosensor technology. Int Immunopharmacol 5: 1007-1017.
16. Ingalls RR, Heine H, Lien E, Yoshimura A, Golenbock D, (1999). Lipopolysaccharide recognition, CD14, and lipopolysaccharide receptors. Infect Dis Clin North Am 13: 341-353.
17. Joh EH, Kim DH, (2011). Kalopanaxsaponin A ameliorates experimental colitis in mice by inhibiting IRAK-1 activation in the NF-κB and MAPK pathways. Br J Pharmacol 162: 1731-1742.
18. Joh EH, Lee IA, Jung IH, Kim DH, (2011). Ginsenoside Rb1 and its metabolite compound K inhibit IRAK-1 activation-the key step of inflammation. Biochem Pharmacol 82: 278-286.
19. Joh EH, Gu W, Kim DH, (2012). Echinocystic acid ameliorates lung inflammation in mice and alveolar macrophages by inhibiting the binding of LPS to TLR4 in NF-κB and MAPK pathways. Biochem Pharmacol 84: 331-340.
20. Jung HC, Eckmann I, Yang SK, Panja A, Fierer J, Morzycka-Wroblewska E, et al. (1995). A distinct array of proinflammatory cytokine is expressed in human colon epithelia cells in response to bacterial invasion. J Clin Invest 95: 55-65.
21. Kawai T, Akira S, (2007). Signaling to NF-kappaB by Toll-like receptors. Trends Mol Med 13: 460-469.
22. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: Reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
23. Kim KA, Gu W, Lee IA, Joh EH, Kim DH, (2012). High fat diet-induced gut microbiota exacerbates inflammation and obesity in mice via the TLR4 signaling pathway. PLoS ONE 7: e47713.
24. Kim SH, Park HH, Lee S, Jun CD, Choi BJ, Kim SY, et al. (2005). The anti-anaphylactic effect of the gall of Rhus javanica is mediated through inhibition of histamine release and inflammatory cytokine secretion. Int Immunopharmacol 5: 1820-1829.et al.
25. Lee K, Kim J, Lee BJ, Park JW, Leem KH, Bu Y, (2012). Protective effects of Galla Rhois, the excrescence produced by the sumac aphid, Schlechtendalia chinensis, on transient focal cerebral ischemia in the rat. J Insect Sci 12: 10. doi: 10.1673/031.012.0110.
26. Lee SH, Park HH, Kim JE, Kim JA, Kim YH, Jun CD, et al. (2007). Allose gallates suppress expression of pro-inflammatory cytokines through attenuation of NF-kappaB in human mast cells. Planta Med 73: 769-773.
27. Lee SJ, Lee IS, Mar W, (2003). Inhibition of inducible nitric oxide synthase and cyclooxygenase-2 activity by 1,2,3,4,6-penta-O-galloyl-beta-D- glucose in murine macrophage cells. Arch Pharm Res 26: 832-839.
28. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
29. Maldonado-Bernal C, Kirschning CJ, Rosenstein Y, Rocha LM, Rios-Sarabia N, Espinosa-Cantellano M, et al. (2005). The innate immune response to Entamoeba histolytica lipopeptidophosphoglycan is mediated by toll-like receptors 2 and 4. Parasite Immunol 27: 127-137.
30. Malekinejad H, Shafie-Irannejad V, Hobbenaghi R, Tabatabaie SH, Moshtaghion SM, (2013). Comparative protective effect of hawthorn berry hydroalcoholic extract, atorvastatin, and mesalamine on experimentally induced colitis in rats. J Med Food 16: 593-601.
31. Moynagh PN, (2005). The NF-kappaB pathway. J Cell Sci 118: 4589-4592.
32. Nakano M, Kurokawa M, Hozumi T, (1998). Suppression of recurrent genital herpes simplex virus type 2 infection by Rhus javanica in guinea pigs. Antiviral Res 39: 25-33.
33. Oh GS, Pae HO, Choi BM, Lee HS, Kim IK, Yun YG, et al. (2004). Penta-O-galloyl-beta-D-glucose inhibits phorbol myristate acetateinduced interleukin-8 gene expression in human monocytic U937 cells through its inactivation of nuclear factor-kappaB. Int Immunopharmacol 4: 377-386.
34. Okamoto Y, Hara T, Ebato T, Fukui T, Masuzawa T, (2013). Brazilian propolis ameliorates trinitrobenzene sulfonic acid-induced colitis in mice by inhibiting Th1 differentiation. Int Immunopharmacol 16: 178-183.
35. Pan MH, Lin-Shiau SY, Ho CT, Lin JH, Lin JK, (2000). Suppression of lipopolysaccharide-induced nuclear factor-kappaB activity by theaflavin-3,3′-digallate from black tea and other polyphenols through down-regulation of IkappaB kinase activity in macrophages. Biochem Pharmacol 59: 357-367.
36. Paradkar PN, Blum PS, Berhow MA, Baumann H, Kuo SM, (2004). Dietary isoflavones suppress endotoxin-induced inflammatory reaction in liver and intestine. Cancer Lett 215: 21-28.
37. Park EJ, Zhao YZ, An RB, Kim YC, Sohn DH, (2008). 1,2,3,4,6-Penta-O- galloyl-beta-D-glucose from Galla Rhois protects primary rat hepatocytes from necrosis and apoptosis. Planta Med 74: 1380-1383.
38. Pasternak BA, D'Mello S, Jurickova II, Han X, Willson T, Flick L, et al. (2010). Lipopolysaccharide exposure is linked to activation of the acute phase response and growth failure in pediatric Crohn's disease and murine colitis. Inflamm Bowel Dis 16: 856-869.
39. Pendyala S, Walker JM, Holt PR, (2012). A high-fat diet is associated with endotoxemia that originates from the gut. Gastroenterology 142: 1100-1101.
40. Peris-Bondia F, Latorre A, Artacho A, Moya A, D'Auria G, (2011). The active human gut microbiota differs from the total microbiota. PLoS ONE 6: e22448.
41. Radema SA, van Deventer SJ, Cerami A, (1991). Interleukin 1 beta is expressed predominantly by enterocytes in experimental colitis. Gastroenterology 100: 1180-1186.
42. Rafii F, van Embdin R, van Lieshout LMC, (1999). Changes in bacterial enzymes and PCR profiles of fecal bacteria from a patient with ulcerative colitis before and after antimicrobial treatments. Dig Dis Sci 44: 637-642.
43. Ren Z, Zhu B, Wang D, Ma E, Su D, Zhong Y, (2008). Comparative population structure of Chinese sumac aphid Schlechtendalia chinensis and its primary host-plant Rhus chinensis. Genetica 132: 103-112.
44. Sandborn WJ, Hanauer SB, (2003). Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment Pharmacol Ther 17: 29-42.
45. Sann H, Erichsen JV, Hessmann M, Pahl A, Hoffmeyer A, (2013). Efficacy of drugs used in the treatment of IBD and combinations thereof in acute DSS-induced colitis in mice. Life Sci 92: 708-718.
46. Shanahan F, (2002). Crohn's disease. Lancet 359: 62-69.
47. Shim YJ, Doo HK, Ahn SY, Kim YS, Seong JK, Park IS, et al. (2003). Inhibitory effect of aqueous extract from the gall of Rhus chinensis on alpha-glucosidase activity and postprandial blood glucose. J Ethnopharmacol 85: 283-287.
48. Soudi S, Zavaran-Hosseini A, Muhammad Hassan Z, Soleimani M, Jamshidi Adegani F, Hashemi SM, (2013). Comparative study of the effect of LPS on the function of BALB/c and C57BL/6 peritoneal macrophages. Cell J 15: 45-54.
49. Tak PP, Firestein GS, (2001). NF-kappaB: a key role in inflammatory diseases. J Clin Invest 107: 7-11.
50. Ukil A, Maity S, Das PK, (2006). Protection from experimental colitis by theaflavin-3,3'-digallate correlates with inhibition of IKK and NF-kappaB activation. Br J Pharmacol 149: 121-131.
51. Wu M, Gu Z, (2009). Screening of bioactive compounds from moutan cortex and their anti-inflammatory activities in rat synoviocytes. Evid Based Complement Alternat Med 6: 57-63.
52. Yokozawa T, Chen CP, Tanaka T, Kitani K, (2000). A study on the nitric oxide production-suppressing activity of Sanguisorbae Radix components. Biol Pharm Bull 23: 717-722.
53. Zhang J, Li L, Kim SH, Hagerman AE, Lü J, (2009). Anti-cancer, anti-diabetic and other pharmacologic and biological activities of penta-galloyl-glucose. Pharm Res 26: 2066-2080.